Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis (Q34316358)

1 August 2017

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis (English)

1 reference

1 August 2017

1 reference

Edward B Rubenstein

1

1 reference

1 August 2017

Douglas E Peterson

2

1 reference

1 August 2017

Mark Schubert

3

1 reference

1 August 2017

Dorothy Keefe

4

1 reference

1 August 2017

Deborah McGuire

5

1 reference

1 August 2017

Joel Epstein

6

1 reference

1 August 2017

Linda S Elting

7

1 reference

1 August 2017

Philip C Fox

8

1 reference

1 August 2017

Catherine Cooksley

9

1 reference

1 August 2017

Stephen T Sonis

10

1 reference

1 August 2017

Mucositis Study Section of the Multinational Association for Supportive Care in Cancer

11

1 reference

1 August 2017

International Society for Oral Oncology

12

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

1 August 2017

1 reference

1 August 2017

100

1 reference

1 August 2017

2026-2046

1 reference

1 August 2017

9 Suppl

1 reference

Treatment of radiation- and chemotherapy-induced stomatitis

1 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Oral and pharyngeal candidiasis. Topical agents for management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Applicability of clinical trial results to primary care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Rules of evidence and clinical recommendations on the use of antithrombotic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Rating the quality of evidence for clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Quality of life and oral function following radiotherapy for head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

An efficacious oral health care protocol for immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Oral complications during treatment of malignant diseases in childhood: effects of tooth brushing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Implementation of an oral care standard for leukemia and transplantation patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Incidence of oral complications and application of a preventive protocol in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Qualified nurses lack adequate knowledge related to oral health, resulting in inadequate oral care of patients on medical wards.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Mucositis management practices for hospitalized patients: national survey results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The development of patient information leaflets. Care of the mouth after radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Management of oral complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prolonged morphine self-administration and addiction liability. Evaluation of two theories in a bone marrow transplant unit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Use of patient-controlled analgesia for pain control for children receiving bone marrow transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Patient-controlled analgesic infusions: alfentanil versus morphine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Patient-controlled analgesic administration. A comparison of steady-state morphine infusions with bolus doses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Adolescents use patient-controlled analgesia effectively for relief from prolonged oropharyngeal mucositis pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Patient-controlled versus staff-controlled analgesia with pethidine after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Potential uses of topical opioids in palliative care--report of 6 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Palliation of radiation-related mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Efficacy of treatment to relieve mucositis-induced discomfort

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Oral and maxillofacial cancer pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Inhibition of fluorouracil-induced stomatitis by oral cryotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Radiation-induced proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Argon laser therapy for hemorrhagic radiation proctitis: long-term results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Argon beam coagulation for treatment of symptomatic radiation-induced proctitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Treatment of radiation proctitis with argon plasma coagulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Hyperbaric oxygen treatment for radiation proctitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prospective evaluation of formalin therapy for radiation proctitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Formalin instillation for refractory radiation-induced hemorrhagic proctitis. Report of 16 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Severe hemorrhagic radiation proctitis advancing to gradual cessation with hyperbaric oxygen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Nd:YAG laser treatment for bleeding from radiation proctitis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Octreotide in the treatment of severe chemotherapy-induced diarrhea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Use of radiation with or without WR-2721 in advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Pain relief of oral ulcer by dibucaine-film

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Use of N-butyl-2-cyanoacrylate in oral surgery: biological and clinical evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Gelclair: managing the symptoms of oral mucositis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Dexamethasone as an adjunct in oropharyngeal obstruction in a patient with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Vitamin E in the treatment of chemotherapy-induced mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Topical butyrate for acute radiation proctitis: randomised, crossover trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Glutamine for irinotecan diarrhea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20163

7 January 2021

Identifiers

DOI

10.1002/CNCR.20163

1 reference

1 August 2017

1 reference